HK1166704B - Method for prophylaxis of influenza using vaccine for intranasal administration - Google Patents

Description

Technical Field

The present invention relates to a vaccine for the prophylaxis of influenza, and a method for the prophylaxis of influenza.

Background Art

Influenza is a viral infectious disease that repeatedly becomes epidemic with different antigen every year. The vaccines approved in Japan for the prophylaxis of influenza are those for subcutaneous administration. Since the vaccination induces an IgG antibody having a neutralizing activity in the serum, it is highly effective for preventing progression of the condition into a more severe one such as pneumonia and the like. In the upper airway mucosa, which is the infection site, however, IgA is the main prophylactic component. Since IgA is not induced by subcutaneous administration, the infection-preventive effect is not sufficient. Therefore, the development of an infection-preventive vaccine has been desired for a long time.

The present inventors have developed an influenza vaccine for mucosal administration comprising a double-stranded RNA and an influenza virus antigen, which is superior in the infection-preventive effect ( WO2005/014038 ).

Disclosure of the Invention

It is therefore an object of the present invention to provide a novel vaccine which is useful for the prophylaxis of influenza, and a method for the prophylaxis of influenza.

To achieve the.above-mentioned object, the present inventors have tried to examine the effects of vaccines by adding various components, and completed the present invention.

Accordingly, the present invention provides the following.

1. [1] A vaccine composition for nasal mucosal administration, comprising (i) an influenza virus antigen, (ii) polyriboinosinic polyribocytidylic acid (poly (I:C)), poly (I:CxU) or poly (IxU:C), and (iii) a carboxyvinyl polymer, wherein x is on average a number from 3 to 40.
2. [2] The composition of [1], wherein the aforementioned antigen is a subunit antigen or an inactivated antigen.
3. [3] The composition of [2], wherein the aforementioned subunit antigen comprises at least one subunit antigen selected from the group consisting of HA, NA, M1, M2, NP, PB1, PB2, PA and NS2 of influenza virus.
4. [4] The composition of [2], wherein the aforementioned subunit antigen comprises at least one subunit antigen selected from the group consisting of HA and NA.
5. [5] The composition of [1], wherein the aforementioned poly (I:CxU) is poly (I:C₁₂U).
6. [6] A vaccine composition comprising an effective amount of (i) an influenza virus antigen, (ii) poly (I:C), poly (I:C_xU) or poly (I_xU:C), and (iii) a carboxyvinyl polymer, wherein x is on average a number from 3 to 40, said composition being for use in a method of preventing influenza, comprising a step of administering said composition at least once to the nasal mucosa of a subject in need thereof.
7. [7] The composition for use according to [6], wherein the aforementioned antigen is a subunit antigen or an inactivated antigen.
8. [8] The composition for use according to [7], wherein the aforementioned subunit antigen comprises at least one subunit antigen selected from the group consisting of HA, NA, M1, M2, NP, PB1, PB2, PA and NS2 of influenza virus.
9. [9] The composition for use according to [7], wherein the aforementioned subunit antigen comprises at least one subunit antigen selected from the group consisting of HA and NA.
10. [10] The composition for use according to [6], wherein the aforementioned poly (I:C_xU) is poly (I:C₁₂U).
11. [11] The composition for use according to [6], wherein the aforementioned method comprises administering the composition at least twice.
12. [12] The composition for use according to [11], wherein the aforementioned method comprises administering the composition at an interval of at least 1 week.

The characteristics and the advantages of the present invention will be apparent from the detailed description of the invention below.

Brief Description of the Drawings

• Figure 1 shows an immune response in a nasal administration test of an influenza vaccine comprising Ampligen and a CVP base in combination.
• Figure 2 is a flow chart of mouse immunity test in Example 2.
• Figure 3 is a summary of the vaccine administration test in Example 2.
• Figure 4 is a flow chart of monkey immunity test in Example 3.
• Figure 5 shows the results of Serum IgG ELISA in Example 3.
• Figure 6 shows the results of nasal swab IgA ELISA in Example 3.
• Figure 7 shows a summary of the vaccine administration test in Example 3.

Detailed Description of the Invention

In the present invention, the influenza virus includes any subtype known at present, and subtypes which will be isolated and identified in the future. Since no epidemic has been heretofore observed in human and human infection needs to be effectively prevented hereafter, the influenza virus is preferably a subtype consisting of a combination of a type selected from H1 - H16 excluding H1 and H3 (i.e., H2 and H4 - 16) and a type selected from N1 - N9. These subtypes are also called new type of influenza virus. The aforementioned subtype is more preferably a subtype consisting of a combination of a type selected from H5, H7 and H9 and a type selected from N1 - N9. The influenza virus may be one type of strain belonging to the same subtype, or two or more types of strains belonging to the same subtype, or two or more types of strains belonging to different subtypes.

The influenza virus antigen contained in the vaccine composition of the present invention is largely divided into an inactivated antigen and a subunit antigen.

The term "inactivated antigen" as used herein refers to an antigen deprived of infectivity, used as a vaccine antigen; such antigens include, but are not limited to, complete virus particle virions, incomplete virus particles, virion-constituting particles, virus non-structural proteins, antigens that protect against infections, neutralizing reaction epitopes and the like. The term "inactivated antigen" as used herein refers to an antigen deprived of infectivity, but retaining immunogenicity; when such an antigen is used as a vaccine, it is called an "inactivated vaccine." Examples of the inactivation methods of antigens include, but are not limited to, physical (e.g., X-ray irradiation, heat, ultrasound), chemical (formalin, mercury, alcohol, chlorine) or other procedures. Subunit antigen per se also falls within the definition of inactivated antigen because they have usually lost infectivity. Alternatively, a killed virus may be used.

The term "subunit antigen" as used herein refers to a component derived from an influenza virus. The subunit antigen includes hemagglutinin (HA), neuraminidase (NA), matrices (Ml, M2), non-structures (NS), polymerases (PB1, PB2: basic polymerases 1 and 2, acidic polymerase (PA)), nuclear proteins (NP) and the like, with preference given to HA or NA, which is exposed to the surface of the virus particle. Currently known types of HA are HA1 to HA16, and known types of NA are NA1 to NA9. The subunit antigen may be purified from a pathogen such as a naturally occurring virus, or may be prepared by a synthetic or recombinant technology. Such methods are well known and in common use in the art, and can be performed using commercially available equipment, reagents, vectors and the like.

The amount of the influenza virus antigen to be contained in the vaccine composition of the present invention is not particularly limited as long as it is sufficient to produce secretary IgA, and can be appropriately determined in consideration of the ratio to the below-mentioned poly (I:C) or a derivative thereof. When HA is used as an antigen, for example, its concentration is preferably 10 - 500 µg HA/mL (based on HA), more preferably 30 - 400 µg HA/mL (based on HA). The aforementioned concentration is obtained by measuring the concentration of HA protein.

Poly(I:C) as contained in the vaccine composition of the present invention is a double-stranded RNA (dsRNA) comprising polyinosinic acid (pI) and polycitidic acid (pC).

A derivative of poly (I:C) is poly (I:C_xU) or poly (I_xU:C) (where x is on average a number from 3 to 40). Preferably, a derivative of poly (l:C) is poly (I:C₁₂U) or poly (C:I₁₂U), which is commercially available under the trade name Ampligen™.

Poly (l:C) or a derivative thereof is supplied in a size sufficient to produce secretory IgA. Examples of such sizes include 100 bp or more, with preference given to sizes of 300 bp or more, which sizes, however, are not to be construed as limiting. Examples of the upper limit of size include, but are not limited to, 10⁸ bp.

Poly (I:C) or a derivative thereof is present at a concentration sufficient to produce secretory IgA. Such a concentration of poly (I:C) or a derivative thereof is, for example, 0.1 to 10 mg/mL, more preferably 0.5 to 2 mg/mL, and still more preferably about 1 mg/mL (e.g., 0.8 to 1.2 mg/mL).

The weight ratio of the influenza virus antigen and poly (I:C) or a derivative thereof to be contained in the vaccine composition of the present invention is recommended to be 1:1 - 1:50.

A carboxyvinyl polymer (CVP) contained in the vaccine composition of the present invention is a hydrophilic polymer which is produced by polymerization of acrylic acid as the main monomer component and includes conventional ones such as Carbopol™ commercially available from Lubrizol Advanced Materials, Inc. US and the like. The concentration of CVP used in the present invention is generally in the range of 0.1 - 2.0 % by weight.

The vaccine composition of the present invention may contain a water-soluble basic substance for the purpose of thickening CVP. The water-soluble basic substance includes, for example, inorganic bases (e.g., sodium hydroxide, potassium hydroxide, ammonia, etc.), and organic bases such as alkylamines (e.g., methylamine, ethylamine, propylamine, etc.), dialkylamines (e.g., dimethylamine, diethylamine, dipropylamine, etc.), trialkylamines (e.g., trimethylamine, triethylamine, tripropylamine, etc.), alkanolamines (e.g., methanolamine, ethanolamine, propanolamine, etc.), dialkanolamines (e.g., dimethanolamine, diethanolamine, dipropanolamine, etc.), trialkanolamines (e.g., trimethanolamine, triethanolamine, tripropanolamine, etc.), amino acids (e.g., arginine, lysine, ornithine, etc.) and the like. These water-soluble bases are used in an amount which is necessary for neutralization to adjust the pH value of CVP aqueous solution to a desired pH.

The pH value of the vaccine composition of the present invention is adjusted to the desired pH with a water-soluble basic substance or other pH adjustors taking into consideration the stability or absorption of an influenza virus antigen. Preferable pH range is 6.0 - 8.0.

Adjustment of the viscosity can be performed depending on the vaccine dosage form. For example, CVP corresponding to 0.1 - 2.0 % by weight is thickened with a water-soluble basic substance and the viscosity is adjusted by applying an outside shearing force, or the viscosity is adjusted with a viscosity modulating agent and an outside shearing force, whereby a base managed to suit the spray angle and spray density from a sprayer is prepared. Thereafter, an influenza virus antigen and poly (I:C) are admixed.

The vaccine composition of the present invention may contain a suitable active medicament, diluent, bactericide, preservative, surfactant, stabilizer and the like which can be used together with the vaccine.

The present invention relates to a method of preventing influenza, comprising a step of administering a vaccine composition comprising an effective amount of an influenza virus antigen and poly (I:C) or a derivative thereof, and a carboxyvinyl polymer at least once to the nasal mucosa of a subject in need thereof.

The subject of administration of the vaccine composition of the present invention includes, but is not limited to, mammals including human, birds and the like.

Nasal mucosal administration of the vaccine composition can be performed in an appropriate form. Various methods such as spraying, coating, or direct dripping of a vaccine liquid can be used.

Administration frequency of the vaccine composition of the present invention is at least once, preferably at least twice, in view of the effectiveness. Additional administration is sometimes called booster immunization. Booster immunization makes it possible to achieve a higher infection-protective effect. The interval of booster immunization is recommended to be at least 1 week, preferably 1 to 4 weeks.

The present invention is hereinafter described in more detail by means of the following examples, which, however, are not to be construed as limiting the present invention.

(Example 1)

Nasal administration test of whole virion vaccine containing Ampligen and CVP in combination for new type of influenza, using mouse

In the development of an influenza vaccine for nasal administration, a vaccine corresponding to pandemic influenza is highly important and highly urgent as compared to vaccine for seasonal influenza, and needs to be preferentially developed. Therefore, a sample vaccine containing a vaccine for new type of influenza (PR8-IBCDC-RG2 strain: attenuated virus strain of A/Indo/5/2005 (H5N1)) and Ampligen in a 10-fold amount of HA antigen was prepared in the same manner as for seasonal influenza HA vaccine. The sample vaccine contained, as an additive for enhancing an immune response in the nasal mucosa by delaying the clearance of vaccine from the nasal mucosa, a CVP base [mixture of 0.55% CVP, 1.2% L-arginine, 1% glycerin] also applied to allergy medicines.

For a nasal administration test, 7-week-old female BALB/c mice were used (5 per group), and antigen was administered at 0.033 - 1 µg HA/head. As a comparison control, a group for which Ampligen was added to vaccine in a 10-fold amount of HA antigen and CVP base was not added, a group for which Ampligen was added to vaccine in a 20-fold amount of HA antigen and CVP base was not added, a group for which CVP alone was added to vaccine, a group to which vaccine without addition was nasally administered, and a group to which vaccine without addition was intramuscularly administered were prepared. The vaccine was administered twice at 3-week intervals, and nasal washings and serum were recovered 2 weeks after booster. Specific IgA-ELISA antibody titer of the nasal washings was measured, and the antibody titers of hemagglutination inhibition (HI), neutralizing antibody and specific IgG-ELISA of the serum were measured. Since the sample vaccine had high viscosity, the administration method was changed from conventional nasal drip using a micropipette to injection by inserting about 4 mm of a blunt needle (27G, 0.4 mmx38 mm) set to a microsyringe.

The results are shown in Tables 1 - 9. [Table 1]

A/Hiroshima HA vaccine+Poly (I:C) or Ampligen (lot comparison)
group	antigen	administration route	dose	numbers/ group	antigen (µg HA or ptn)	Poly (I:C)	Ampligen (new)
1	A/Hiroshima /52/2005 (H3N2) HA vaccine	in	2 µl to each nasal cavity	5	0.1
2					0.1	0.1
3					0.1	1
4			2.7 µl to each nasal cavity		0.1	10
5					0.1		0.1
6					0.1		1
7					0.1		10
8		SC	100		0.1
9	whole virion	in			0.2
10	none (control)			10

• 1st:1/28 BALB/c mice (7w♀)
• 2nd:2/18
• Sampling:2/28
• Antigen was A/Hiroshima/52/2005 (H3N2) HA vaccine FTHAG0712 (1205 µg HA/mL) or whole virion vaccine (344 µg ptn/mL)
• poly(I:C) [SIGMA P-0913] was adjusted to 1.88 mg/mL Ampligen (new) was Lot0701HE

[Table 2]

exp. A/Hiroshima HA vaccine+Poly (I:C) or Ampligen NW IgA ELISA
group		1	2	3	4	5	6	7	8	9	10
antigen		A/Hiroshima /52/2005 (H3N2) HA vaccine								whole virion	none (control)
administration route		in							sc	in
dose		2 µl to each nostril (nasal cavity)			2.7 µl to each nostril (nasal cavity)	2 µl to each nostril (nasal cavity)			100 µl	2 µl to each nostril (nasal cavity)
numbers/group		5									10
antigen (µg HA or ptn)		0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2
adjuvant (µg/head)	Poly (I:C)		0.1	1	10
	Ampligen (new)					0.1	1	10
animal No.	1	1	1	1	16	1	1	128	1	64	1
	2	1	32	16	16	128	4	32	1	8	1
	3	1	2	16	128	32	32	4	1	8	1
	4	1	16	32	256	32	8	16	1	32	1
	5	1	64	32	64	2	2	16	1	32	1
geometric mean		1.0	9.2	12.1	55.7	12.1	4.6	21.1	1.0	21.1	1.0
SD		0.0	26.2	13.0	100.6	52.0	12.9	50.6	0.0	23.0	0.0
geometric mean titer (GMT,2^n)		0.0	3.2	3.6	5.8	3.6	2.2	4.4	0.0	4.4	0.0
positive conversion ratio (≥32,%)		0.0	40.0	40.0	60.0	60.0	20.0	40.0	0.0	60.0	0.0

[Table 3]

exp. A/Hiroshima HA vaccine+Poly (I:C) or Ampligen Serum IgG
group		1	2	3	4	5	6	7	8	9	10
antigen		A/Hiroshima /52/2005 (H3N2) HA vaccine FTHAG0712								whole virion	none (control)
administration route		in							sc	in
dose		2 µl to each nostril (nasal cavity)			2.7 µl to each nostril (nasal cavity)	2 µl to each nostril (nasal cavity)			100 µl	2 µl to each nostril (nasal cavity)
numbers/group		5									10
antigen (µg HA or ptn)		0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2
	Poly (I:C)		0.1	1	10
	Ampligen (new)					0.1	1	10
animal No.	1	50	50	^100	6400	100	50	1600	51200	1600	50
	2	50	800	200	400	400	400	800	51200	400	50
	3	50	400	1600	6400	6400	1600	100	51200	200	50
	4	50	200	800	3200	200	6400	50	25600	400	100
	5	50	400	400	800	200	50	800	25600	1600	50
geometric mean		50.0	263.9	400.0	2111.2	400.0	400.0	348.2	38802.3	606.3	53.6
SD		0.0	282.0	609.9	2906.5	2763.7	2703.5	634.0	14021.7	698.6	15.8
geometric mean titer (GMT,2^n)		5.6	8.0	8.6	11.0	8.6	8.6	8.4	15.2	9.2	5.7

[Table 4]

exp. A/Hiroshima HA vaccine+Poly (I:C) or Ampligen Serum HI
group		1	2	3	4	5	6	7	8	9	10
antigen		A/Hiroshima /52/2005 (H3N2) HA vaccine								whole virion	none (control)
administration route		in							sc	in
dose		2 µl to each nostril (nasal cavity)			2.7 µl to each nostril (nasal cavity)	2 µl to each nostril (nasal cavity)			100 µl	2 µl to each nostril (nasal cavity)
numbers/group		5									10
antigen (µg HA or ptn)		0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2
	Poly (I:C)		0.1	1	10
	Ampligen (new)					0.1	1	10
animal No.	1	5	5	5	40	5	5	5	160	5	5
	2	5	5	5	5	5	5	5	320	5	5
	3	5	5	5	40	5	5	5	320	5	5
	4	5	5	5	20	5	10	5	160	5	5
	5	5	5	5	5	5	10	5	80	5	5
geometric mean		5.0	5.0	5.0	15.2	5.0	6.6	5.0	183.8	5.0	5.0
SD		0.0	0.0	0.0	17.5	0.0	2.7	0.0	107.3	0.0	¨0.0
geometric mean titer (GMT,2^n)		2.3	2.3	2.3	3.9	2.3	2.7	2.3	7.5	2.3	2.3
seroconversion rate (≥40,%)		0.0	0.0	0.0	40.0	0.0	0.0	0.0	100.0	0.0	0.0

[Table 5]

Ampligen pharmacological effect preliminary test: H5 Indonesia whole virion (2008.9.25) test group constitution
group	antigen (µg/dose)	Ampligen (µg/dose)	CVP (%)	n	administration route	dose (µl)	note
1	0.3	3.00		5	in	2.0	antigen:Ampligen= 1:10
2	0.1	1.00		5	in	2.0
3	0.033	0.33		5	in	2.0
4	0.3	3.00	0.55	5	in	2.0	antigen:Ampligen= 1:10 + CVP
5	0.1	1.00	0.55	5	in	2.0
6	0.033	0.33	0.55	5	in	2.0
7	0.3	6.00		5	in	2.0	antigen:Ampligen= 1:10
8	0.1	2.00		5	in	2.0
9	0.033	0.67		5	in	2.0
10	0.3		0.55	5	in	2.0	antigen + CVP
11	0.1		0.55	5	in	2.0
12	0.033		0.55	5	in	2.0
13	0.3			5	in	2.0	antigen alone
14	0.1			5	in	2.0
15	0.033			5	in	2.0
16	0.3			5	im	50.0	antigen alone, intramuscular control
17				10	in	2.0	saline control

• 2008.9.30 1st immunization
• 2008.10.21 2nd immunization
• 2008.11.4 Sampling
• Antigen was attenuated virus strain of PR8-IBCDC-RG2
• strain:A/Indo/5/2005(H5N1), Lot FPBMW0612-0 3110 µg PTN/mL. about 1048 µg HA/mL))
• Ampligen is manufactured by Hemispherx, Lot R-01:45.7 mg/mL
• CVP is manufactured by Toko Yakuhin Kogyo, Lot No.INF-9B8, base for preparation (#03-01)
• Remark 1: prepared for 300 mice
• antigen: 300 mice X 0.3 µg/head/1.048 µg/µl=85.9 µl BALB/c mice, 7w ♀, were used.

[Table 6]

Ampligen pharmacological effect preliminary test: H5 Indonesia whole virion (2008.9.25-) NW IgA (2008.11.6)
group		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17
antigen (µg/dose)		0.3	0.1	0.033	0.3	0.1	0.033	0.3	0.1	0.033	0.3	0.1	0.033	0.3	0.1	0.033	0.3
Ampligen (µg/dose)		3.00	1.00	0.33	3.00	1.00	0.33	6.00	2.00	0.67
CVP (%)					0.55	0.55	0.55				0.55	0.55	0.55
administration method		in	in	in	in	in	in	in	in	in	in	in	in	in	in	in	im	in
animal No.	1	32	32	4	256	128	16	8	8	4	16	32	8	16	16	1	1	1
	2	16	16	8	512	128	16	32	4	4	32	2	2	4	8	8	1	1
	3	32	32	4	128	128	2	16	8	2	16	2	1	16	2	4	1	2
	4	16	16	2	64	512	64	32	32	2	64	2	2	8	4	16	2	2
	5	8	32	1	64	64	64	64	8	8	4	1	4	8	64	2	2	2
geometric mean titer (GMT)		18.4	24.3	3.0	147.0	147.0	18.4	24.3	9.2	3.5	18.4	3.0	2.6	9.2	9.2	4.0	1.3	1.5
mean titer (2^n)		4.2	4.6	1.6	7.2	7.2	4.2	4.6	3.2	1.8	4.2	1.6	1.4	3.2	3.2	2.0	0.4	0.6
positive conversion ratio (titer≥32, %)		40	60	0	100	100	40	60	20	0	40	20	0	0	20	0	0	0

[Table 7]

Ampligen pharmacological effect preliminary test: H5 Indonesia whole virion (2008.9.25-) Serum NT (2008.11.19)
group		4	5	6	13	16
antigen (µg/dose)		0.3	0.1	0.033	0.3	0.3
Ampligen (µg/dose)		3.00	1.00	0.33
CVP(%)		0.55	0.55	0.55
Poly L-Arg (µg/dose)
administration method		in	in	in	in	im
animal No.	1	80	160	80	20	160
	2	1280	10	40	10	80
	3	80	160	40	10	320
	4	160	160	160	10	80
	5	160	160	40	10	640
geometric mean titer (GMT)		183.8	91.9	60.6	11.5	183.8
mean titer (2^n)		7.5	6.5	5.9	3.5	7.5

[Table 8]

Ampligen pharmacological effect preliminary test: H5 Indonesia whole virion (2008.9.25-) Serum HI (2008.11)
group		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17
antigen (µg/dose)		0.3	0.1	0.033	0.3	0.1	0.033	0.3	0.1	0.033	0.3	0.1	0.033	0.3	0.1	0.033	0.3
Ampligen (µg/dose)		3.00	1.00	0.33	3.00	1.00	0.33	6.00	2.00	0.67
CVP (%)					0.55	0.55	0.55				0.55	0.55	0.55
administration method		in	in	in	in	in	in	in	in	in	in	in	in	in	in	in	im	in
animal No.	1	5	5	5	5	10	5	5	5	5	5	5	5	5	5	5	10	5
	2	5	5	5	40	5	5	5	5	5	5	5	5	5	5	5	5	5
	3	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	20	5
	4	5	5	5	10	10	20	10	5	5	5	5	5	5	5	5	5	5
	5	5	5	5	5	5	5	10	5	5	5	5	5	5	5	5	10	5
geometric mean titer (GMT)		5.0	5.0	5.0	8.7	6.6	6.6	6.6	5.0	5.0	5.0	5.0	5.0	5.0	5.0	5.0	8.7	5.0
mean titer (2^n)		2.3	2.3	2.3	3.1	2.7	2.7	2.7	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	3.1	2.3
seroconversion rate (≥40.%)		0	0	0	20	0	0	0	0	0	0	0	0	0	0	0	0	0

[Table 9]

Ampligen pharmacological effect preliminary test: H5 Indonesia whole virion (2008.9.25-) Serum IgG (2008.11.6)
group		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17
antigen (µg/dose)		0.3	0.1	0.033	0.3	0.1	0.033	0.3	0.1	0.033	0.3	0.1	0.033	0.3	0.1	0.033	0.3
Ampligen (µg/dose)		3.00	1.00	0.33	3.00	1.00	0.33	6.00	2.00	0.67
CVP (%)					0.55	0.55	0.55				0.55	0.55	0.55
administration method		in	in	in	in	in	in	in	in	in	in	in	in	in	in	in	im	in
animal No.	1	1600	1600	400	12800	6400	1600	6400	200	50	800	400	400	1600	200	50	12800	50
	2	1600	1600	400	51200	6400	800	6400	800	800	6400	50	50	3200	3200	200	12800	50
	3	800	800	200	6400	12800	1600	6400	800	100	51200	50	100	1600	50	200	25600	50
	4	800	400	200	6400	25600	3200	6400	1600	100	800	200	100	3200	1600	400	12800	50
	5	800	400	200	12800	12800	3200	12800	800	1600	800	100	200	1600	3200	50	12800	50
geometric mean titer (GMT)		1055.6	800.0	263.9	12800.0	11143.0	1837.9	7351.7	696.4	229.7	2785.8	114.9	132.0	2111.2	696.4	132.0	14703.3	50.0
mean titer (2^n)		10.0	9.6	8.0	13.6	13.4	10.8	12.8	9.4	7.8	11.4	6.8	7.0	11.0	9.4	7.0	13.8	5.6
positive conversion ratio (titer≥32, %)		100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	200

(Results) Nasal administration test of whole virion vaccine for new type of influenza, containing Ampligen and CVP base in combination, and using mouse

A remarkable immunoenhancing effect was confirmed in the mucosa and serum in the group administered with a vaccine containing Ampligen and a CVP base in combination, which was not found in the group administered with Ampligen alone. The specific IgG, HI and neutralizing antibody titer (NT) of the serum increased to levels equivalent to those of the intramuscular injection group (no adjuvant).

A sample pandemic influenza vaccine containing, as an additive for enhancing an immune response in the nasal mucosa, a CVP base also applied to allergy medicines in combination, was prepared and used for a nasal administration test.

We investigated the convenience of nasal administration method at this time and obtained unexpected effects of a remarkably improved immune response of the nasal mucosa, a specific antibody titer of the serum, which is equivalent to that of intramuscular injection without adjuvant, and the like. Hence, a more practical vaccine was obtained.

(Example 2) Evaluation system via transnasal immunity in mouse (consideration of optimal dose and administration frequency for mouse)

The optimal dose and administration frequency for mouse were examined based on the measurements of serum specific IgG antibody titer and HI antibody titer after addition of Ampligen, CVP and the like to an antigen, and the comparison with existing vaccines having known composition and known administration method, and using a "new type influenza virus antigen at high concentration".

(Materials) 1. New type influenza vaccine stock solution and virus for evaluation of cross-reactive antibody titer:

new type influenza vaccine stock solution: lot No.; FPBMW0612-c (protein concentration: 3110 µg/mL, HA content 992 µg HA/mL, origin virus strain: A/Indo/5/2005 (H5N1)/PR8-IBCDC-RG2) (The Research Foundation for Microbial Diseases of Osaka University)

2. Original strain of virus and inactivated vaccine antigen:

for measurement of specific antibody titer:

• A/Indo/5/2005(H5N1)/PR8-IBCDC-RG2 strain: attenuated strain (clade 2.1) of A/Indonesia/5/2005 (H5N1)

for measurement of cross-reactive antibody titer:

• A/Anhui/01/2005(H5N1)/PR8-IBCDC-RG5 strain: attenuated strain (clade 2.3) of A/Anhui/01/2005 (H5N1)
• A/bar-headed goose/Qinghai/lA/2005 strain: attenuated strain (clade 2.2) of A/Qinghai/1A/2005 (H5N1)
• NIBRG-14 strain: attenuated strain (clade 1) of A/Vietnam/1194/2004 (H5N1)

3. Adjuvant:

Ampligen®: containing Ampligen (2.5 mg/mL) manufactured by Hemispherx

4. Test method

Fig. 2 shows a schematic view of test flows.

A vaccine containing A/Indo/5/2005 (H5N1)/PR8-IBCDC-RG2 virus antigen (obtained by adding Ampligen to a 20-fold concentration of HA antigen, and adding CVP base (1.1% carboxyvinyl polymer, 2.4% L-arginine, 2.0% glycerol) to 50.0 v/v% of the total amount) was transnasally administered to BALB/c mice and samples (nasal swab and serum) were taken 3 weeks later. In this case, samples were not taken from a part of the mice, and booster was given thereto one to three times. The interval between the boosters for mice subjected to two or three times of boosters was 2 weeks. Samples were taken at 2 weeks from the last booster, and immune response was confirmed when all samples were taken. As comparison controls for the confirmation of the effects of Ampligen and CVP base added, a non-addition vaccine transnasal administration group (high dose, medium dose, low dose) with the same antigen dose but free of Ampligen and CVP base and a negative control group (transnasal administration (once) of saline) were set, and a non-addition vaccine intramuscular administration group (high dose) was set for comparison with vaccines having known dosage form and known administration method. From the above-mentioned test, the relationship between dose and administration frequency, and immune response was evaluated. In addition, immune response with a virus strain having different antigenicity was also investigated to obtain findings as to the cross-reactivity.

5. Animals and vaccine (Table 10)

• test animal: BALB/c mouse (♀, 6-week-old when the test was started), 10 mice/group trial vaccine for test consideration and adjuvant dose: high dose group: [0.3 µg HA + 6 µg Ampligen]/dosemedium dose group: [0.1 µg HA + 2 µg Ampligen]/doselow dose group: [0.033 µg HA + 0.66 µg Ampligen]/dose

As negative control, a saline administration group was set. In addition, for confirmation of effects of vaccine addition, non-addition vaccine transnasal administration group (high dose, medium dose, low dose) with the same antigen dose but free of Ampligen and CVP base was set, and an intramuscular administration group (high dose) was set for the comparison with conventional vaccines (known dosage form•administration method). vaccine composition:

• high dose group: [vaccine 0.3 µL + Ampligen 2.4 µL + CVP base 2.5 µL]/dose
• medium dose group: [vaccine 0.1µL + Ampligen 0.8 µL + M/75 PBS (PH 7.2) 1.6 µL + CVP base 2.5 µL]]/dose
• low dose group: [vaccine 0.033 µL + Ampligen 0.26 µL + M/75 PBS (PH 7.2) 2.207 µL + CVP base 2.5 µL]/dose The vaccine for non-addition transnasal administration used as a negative control was obtained by removing Ampligen and CVP base from the above-mentioned composition, and adding M/75 PBS (pH 7.2) in a volume corresponding thereto. In addition, the vaccine for non-addition intramuscular administration was [vaccine 0.3 µL + M/75 PBS (pH 7.2) 49.7 µL]/dose.
• Vaccine administration volume: (Table 11)

The transnasal administration group was administered with 6 µL into one nostril, and the control non-addition vaccine subcutaneous administration group was administered with 50 µL to unilateral femoral area.

6. Measurement items (Tables 12-19)

nasal swab: specific IgA-ELISA antibody titer and cross-reactive IgA-ELISA antibody titer:

• serum specific IgG-ELISA antibody titer, specific HI (hemagglutination inhibition) antibody titer and cross-reactive HI antibody titer, specific neutralizing antibody titer and cross-reactive neutralizing antibody titer were measured. Among the above-mentioned measurement items, the outline of the measurement method of the ELISA antibody titer was as described below.

Vaccine antigen (diluted with 100 mM carbonate buffer (pH 9.6) to protein concentration of 1 µg/mL) was solid phased (4°C, overnight) on a 96-well ELISA plate at 100 µL/well, and washed 3 times with PBS containing 0.1% Tween 20. A sample diluted 2-fold series or negative control was added at 100 µL/well. Then, the plate was incubated at 37°C for 1 hr, and washed 3 times with PBS containing 0.1% Tween 20. An antibody for detection (alkaliphosphatase-labeled anti-mouse IgG or biotin-labeled anti-mouse IgA) was added at 100 µL/well. The plate was incubated at 37°C for 1 hr, and washed 3 times with PBS containing 0.1% Tween 20 (for IgA detection, alkaliphosphatase-labeled streptavidin was added at 100 µL/well, incubated at 37°C for 1 hr, and washed 3 times with PBS containing 0.1% Tween 20). Then, 4-nitrophenylphosphate (1 mg/mL, diluted with 0.1 M diethanolamine (pH 9.8)) was added at 100 µL/well, and the plate was shaded. After incubation at room temperature for 30 min, the absorbance at 405 nm was measured.

The maximum dilution rate that affords an absorbance of sample exceeding the average absorbance of negative control+2SD was taken as the antibody titer of the sample. For specific antibody titer, the same strain as the administration vaccine antigen was used and, for cross-reactive antibody titer, vaccine antigen of a different strain was used. In the following, HI• neutralizing antibody titer were measured in the same manner. specific HI (hemagglutination inhibition) antibody titer and cross-reactive HI antibody titer:

• The test was performed according to the description in the "pathogen detection manual" (edited by National Institute of infectious Diseases). The red blood cells used were derived from chicken.

specific neutralizing antibody titer and cross-reactive neutralizing antibody titer:

• The test was performed according to the description in the "pathogen detection manual" (edited by National Institute of infectious Diseases). The culture after virus infection was performed for 4 days. In addition, a method comprising staining the cells with 0.1% Naphtol Blue Black/0.1% sodium acetate/9% acetic acid, drying the cell culture plate, adding 0.1M sodium hydroxide and measuring the absorbance at 630 nm was used for distinction between virus infectious cells and non-infectious cells.

(Results)

BALB/c mice (♀, 6.5w when test was started) were used, and immune response was examined when the antigen (A/Indonesia/5/2005 (H5N1)) supplemented with ampligen at 20-fold ratio of HA antigen, and CVP was transnasally administered 1 - 4 times, using, as a comparison control, an antigen+Ampligen+CVP transnasal administration group for the first half of the test group and transnasal administration of antigen alone/intramuscular administration of antigen alone/saline transnasal administration for the latter half. The results are shown in Tables 12-19 and Fig. 3.

In the antigen+Ampligen+CVP group, several to dozen-fold mucous membrane IgA/serum IgG and NT antibody titer were observed as compared to the antigen alone transnasal administration group, and the difference was remarkable in the groups with lower dose and less administration frequency.

Conventional common knowledge holds that, as compared to vaccines for subcutaneous or intramuscular administration, transnasal administration-type vaccines show lower specific neutralizing antibody, serum specific IgG antibody titer and HI antibody titer. However, the vaccine evaluated at this time was found to acquire specific neutralizing antibody, serum specific IgG antibody titer and HI antibody titer equivalent to or above those of the vaccines with conventional composition and administration method, by the addition of Ampligen® and the like.

Furthermore, the immune response of the samples obtained by this test with the same strain as the administered antigen and a strain with different antigenicity was examined to confirm cross-reactivity. [Table 11]

Vaccine composition
dose	administration group	vaccine stock solution(µL)	Ampligen (µL)	C\/P (µL)	M/75PBS(pH72) (µL)	total (mL)	note
high dose (0.3µg HA/dose)	1,4,7,10	302.42	2400.0	3000	297.58	6	for 1000 times (transnasal)
moderate dose (0.1µg HA/dose)	2,5,8,11	100.81	800.0	3000	2099.19	6	for 1000 times (transnasal)
low dose (0.033µg HA/dose)	3,6,9,12	33.27	264.0	3000	2702.73	6	for 1000 times (transnasal)
high dose (0.3µg HA/dose)	13,16,19,22	302.42			5697.58	6	for 1000 times (transnasal)
moderate dose (0.1µg HA/dose)	14,17,20,23	100.81			5899.19	6	for 1000 times (transnasal)
low dose (0.033µg HA/dose)	15,18,21,24	3327			5966.73	6	for 1000 times (transnasal)
high dose (0.3µg HA/dose)	25,26,27,28	3024			4969.76	5	for 100 times (muscular injection)
saline	29				600 (saline)		for 100 times (transnasal)

[Table 11]

Whole particles influenza vaccine: A/Indo/5/2005(H5N1) lot No.; FPBMW0612-c (protein concentration: 3110 µg/mL, HA content 992 µg HA/mL) Ampligen (manufactured by Hemispherx): lot; 0701HE (containing 2.5 mg/mL Ampligen) CVP base (manufactured by Toko Yakuhin Kogyo Kabushiki Kaisya): lot INF-N28; carboxyvinyl polymer 1.1%, L-arginine 2.4%, glycerol 2%

[Table 15]

Serum HI test (2009.7.23) cross-reaction (A/VN)
group		4	5	7	8	26	27
antigen amount of administration (µg HA/dose)		0.3	0.1	0.3	0.1	0.3	0.3
administration frequency		3		2		3	2
administration route		transnasal	transnasal	transnasal	transnasal	intramuscular	intramuscular
adjuvant (Ampligen), CVP addition		yes	yes	yes	yes	none	none
animal No.	1	5	20	5	5	5	5
	2	5	5	5	5	5	5
	3	5	5	5	5	20	5
	4	5	5	5	5	10	5
	5	5	10	5	5	5	5
	6	5	5	5	5	5	5
	7	5	20	5	5	5	5
	8	5	20	5	5	5	5
	9	5	5	5	10	5	5
	10	5		5			5
average antibody titer (GMT)		5.0	8.6	5.0	5.4	6.2	5.0
variance		0.0	7.3	0.0	1.7	4.8	0.0
seroconversion rate (antibody titer not less than 40,%)		0·0	0.0	0.0	0.0	0.0	0.0

(Example 3) Administration of transnasal administration-type influenza vaccine (H5N1 type) and immune response evaluation test using Cynomolgus monkeys (Macaca fascicularis)

Based on the relationship between the administration dose, use and immune response obtained by the experiments using mice in Example 2, administration tests were performed using Cynomolgus monkeys (Macaca fascicularis) as an animal close to human, and the dosage form and composition optimal as a transnasal administration-type vaccine were searched and the usefulness from the aspect of infection defense was investigated.

To be precise, (1) search of optimal dosage form/composition by comparison of immune responses after administration of transnasal administration-type vaccine candidates, and (2) evaluation of practicality from the ability to defend against infection by measurement of serum and mucous membrane antibody titers after vaccine inoculation were performed.

The search was performed by immuno-chemical test of serum (influenza HI antibody titer, IgG-ELISA antibody titer and neutralizing antibody titer) and immuno-chemical test of nasal swab (influenza specific IgA-ELISA antibody titer).

(Test method) 1. Influenza vaccine stock solution:

Influenza vaccine (H5N1 strain) stock solution (lot No., FPBMQI0813, protein concentration: 816 µg/mL, HA content 324 µg HA/mL, origin of virus strain: A/Bar-headed Goose/Qinghai/1A/2005 (H5N1))

2. Origin of virus strain and inactivated vaccine antigen to be used for test (for specific antibody titer measurement)

A/Bar-headed Goose/Qinghai/1A/2005 (H5N1) strain: attenuated strain (clade 2.2) of A/Qinghai/1A/2005 (H5N1)

(for cross-reactive antibody titer measurement)

• A/Indo/5/2005 (H5N1)/PR8-IBCDC-RG2 strain: attenuated strain (clade 2.1) of A/Indonesia/5/2005 (H5N1)
• A/Anhui/01/2005 (H5N1)/PR8-IBCDC-RG5 strain: attenuated strain (clade 2.3) of A/Anhui/01/2005 (H5N1)
• NIBRG-14 strain: attenuated strain (clade 1) of A/Vietnam/1194/2004 (H5N1)

3. Adjuvant and additive to be used for test

• Ampligen: manufactured by Hemispherx, (containing 10.61 mg/mL of Ampligen)
• carboxyvinyl polymer (CVP): manufactured by Toko Yakuhin Kogyo Kabushiki Kaisya, lot; INF-619 (containing 1.1% CVP, 2.4% L-arginine and 2% glycerol)
• poly L-arginine: manufactured by SIGMA, catalog No. P-3892, lot; 107K5103 (MW>70,000)

4. Test method

Fig. 4 shows outline of test flows. [Table 20]

Test group constitution:
group	vaccine HA antigen (µg/dose)	Ampligen (µg/ dose)	Poly L-Arg (µg/ dose)	CVP addition	head	note
1	30			-	4	vaccine alone
2	30	600		O	4	trial vaccine
3	30		1500	O	4	Poly L-Arg
4	-			-	1	control group

Anesthesized Cynomolgus monkeys (Macaca fascicularis) was transnasally administered with a vaccine containing A/Bar-headed Goose/Qinghai/1A/2005 (H5N1) strain virus antigen or saline at 3 weeks intervals, using a transnasal administration device with trial actuator (test actuator : manufactured by Toko Yakuhin Kogyo Kabushiki Kaisya, Spray Pump; Apta Pharma, VP-7 type, spraying use) six times by 150 µl (50 µl×3) to each nasal cavity (total 300 µl), and samples (nasal swab and serum) were taken at the time of each administration, and every 2 weeks from the booster up to 12 weeks from the booster. Furthermore, where necessary, blood samples•nasal swab were taken every 2 weeks thereafter.

Animal and vaccine:

• animal: Cynomolgus monkeys (Macaca fascicularis) (male 17 cynomolgus monkeys, 46 - 58 months of age when test was started, body weight 2.8 - 3.5 kg in November 2009), group 1 - group 4: 4 cynomolgus monkeys/group, group 5 (negative control): cynomolgus monkey/group
• trial vaccine for test and adjuvant dose: (1) non-addition vaccine group: [30 µg HA]/dose(2) Ampligen + CVP addition vaccine group: [30 µg HA + 600 µg Ampligen + 0.55% CVP]/dose(3) Poly L-arginine + CVP addition vaccine group: [30 µg HA + 0.5% Poly L-arginine + 0.55% CVP]/dose(4) negative control group: saline

vaccine administration volume: 150 µl for each nasal cavity, total 300 µl 5. Measurement items of each sample

nasal swab: specific IgA-ELISA antibody titer and IgA concentration

The nasal swab was measured for the total IgA concentration and the specific IgA-ELISA antibody titer calculated in the same manner as in Example 2 was amended to be the numerical value per total IgA concentration of 1 µg/mL. serum: specific IgG-ELISA antibody titer, specific, cross-reactive HI (hemagglutination inhibition) antibody titer, specific/cross-reactive neutralizing antibody titer

Among the above-mentioned measurement items, the outline of the measurement method of the ELISA antibody titer was as described below.

Vaccine antigen (diluted with 100 mM carbonate buffer (pH 9.6) to protein concentration of 1 µg/mL) was solid phased (4°C, overnight) on a 96-well ELISA plate at 100 µL/well, and washed 3 times with PBS containing 0.1% Tween 20. A sample diluted 2-fold series or negative control was added at 100 µL/well. Then, the plate was incubated at 37°C for 1 hr, and washed 3 times with PBS containing 0.1% Tween 20. An antibody for detection (alkaliphosphatase-labeled anti-monkey IgG or biotin-labeled anti-monkey IgA) was added at 100 µL/well. The plate was incubated at 37°C for 1 hr, and washed 3 times with PBS containing 0.1% Tween 20. The substrate solution (4-NPP or TMB) was added at 100 µL/well and the mixture was shaded and incubated at room temperature for 30 min.

A stop solution (2M H₂SO₄ solution for 4-NPP or 650 nm stop solution for TMB) was added, and the absorbance (405 nm or 655 nm) was measured.

The maximum dilution rate that affords an absorbance of sample exceeding the average absorbance of negative control+2SD was taken as the antibody titer of the sample. For specific antibody titer, the same strain as the administration vaccine antigen was used and, for cross-reactive antibody titer, vaccine antigen of a different strain was used. In the following, HI antibody titer and neutralizing antibody titer were measured in the same manner. specific HI (hemagglutination inhibition) antibody titer and cross-reactive HI antibody titer: They were measured in the same manner as in Example 2. specific neutralizing antibody titer and cross-reactive neutralizing antibody titer: They were measured in the same manner as in Example 2.

(Results)

The results are shown in Tables 21-30 and Figs. 5-7.

It was confirmed that transnasal spray administration of a vaccine containing Ampligen and CVP to monkey induces specific IgA production in the mucous membrane, and derivation of specific neutralizing antibody in the serum. Since these effects were insufficient with an additive-free vaccine, the usefulness of addition of Ampligen and CVP was confirmed. [Table 21]

Administration of transnasal administration-type influenza vaccine (H5N1-type) and immune response evaluation test using Cynomolgus monkeys (Macaca fascicularis); Vaccine composition
group	vaccine HA antigen (mL) [324 µg HA/mL]	Ampligen (mL) [10.61 mg/mL]	Poly L-Arg (mL) [100 mg/mL]	CVP addition (mL)	M/75 PBS (pH 7.2) (mL)	Note	dose (µL)
1	3.087 (30 µg/dose)	-	-	-	6.913	10 mL min	300
2	3.087 30 µg/dose)	1.885 (600 µg/dose)	-	5.0 (yes)	0.028	10 mL min	300
3	-	-	0.750 (1.5 mg/dose)	-	4.250	5 mL min	100
	3.704 (30 µg/dose)	-	-	4	0.296	8 mL min	200
4		-	-	-	10.000	10 mL min	300

[Table 21]

Influenza vaccine stock solution to be used for test influenza vaccine (H5N1 strain) stock solution: lot No.; FPBMQI0813 (protein concentration: 816 µg/mL, HA content 324 µg HA/mL) origin virus strain: A/Bar-headed Goose/Qinghai/1A/2005 (H5N1) adjuvant and additive to be used for test Ampligen (manufactured by Hemispherx): containing 10.61 mg/mL of Ampligen carboxyvinyl polymer (manufactured by Toko Yakuhin Kogyo Kabushiki Kaisya): lot; INF-619 (containing 1.1% CVP (carboxyvinyl polymer), 2.4% L-arginine and 2% glycerol) poly L-arginine (manufactured by SIGMA, catalog No. P-3892): lot; used after dissolving 107K5103 (MW>70,000) in 100 mg/mL

[Table 22]

Administration of transnasal administration-type influenza vaccine (H5N1-type) and immune response evaluation test (HI) using Cynomolgus monkeys (Macaca fascicularis); before administration (blood samples were collected on 2010.1.28/measured on 2010.2.2)
group		1	2	3	4
vaccine HA antigen (µg/dose)		30	30	30	-
Ampligen (µg/dose)			600
Poly L-Arg (µg/dose)				1500
CVP addition		-	+	+	-
animal No.	1	5	5	5	5
	2	5	5	5
	3	5	5	5
	4	5	5	5
average antibody titer (GMT)		5.0	5.0	5.0	5.0
variance		0.0	0.0	0.0
seroconversion rate (antibody titer not less than 40, %)		0.0	0.0	0.0	0.0

[Table 23]

Administration of transnasal administration-type influenza vaccine (H5N1-type) and immune response evaluation test (HI) using Cynomolgus monkeys (Macaca fascicularis); after once administration (blood samples were collected on 2010.2.18/measured on 2010.2.23)
group		1	2	3	4
vaccine HA antigen (µg/dose)		30	30	30	-
Ampligen (µg/dose)			600
Poly L-Arg (µg/dose)				1500
CVP addition		-	+	+	-
animal No.	1	20	5	5	5
	2	10	5	5
	3	5	5	5
	4	5	10	5	5
average antibody titer (GMT)		8.4	5.9	5.0	5.0
variance		7.1	2.5	0.0
seroconversion rate (antibody titer not less than 40, %)		0.0	0.0	0.0	0.0

[Table 24]

Administration of transnasal administration-type influenza vaccine (H5N1-type) and immune response evaluation test (HI) using Cynomolgus monkeys (Macaca fascicularis); after twice administration (blood samples were collected on 2010.3.4/measured on 2010.3.9)
group		1	2	3	4
vaccine HA antigen (µg/dose)		30	30	30	-
Ampligen (µg/dose)			600
Poly L-Arg (µg/dose)				1500
CVP addition		-	+	+	-
animal No.	1	5	5	5	5
	2	5	5	5
	3	5	5	5
	4	5	5	5
average antibody titer (GMT)		5.0	5.0	5.0	5.0
variance		0.0	0.0	0.0
seroconversion rate (antibody titer not less than 40, %)		0.0	0.0	0.0	0.0

[Table 25]

Administration of transnasal administration-type influenza vaccine (H5N1-type) and immune response evaluation test (HI) using Cynomolgus monkeys (Macaca fascicularis); 2 weeks after twice administration (blood samples were collected on 2010.3.18/measured on 2010.3.24)
group		1	2	3	4
vaccine HA antigen (µg/dose)		30	30	30	-
Ampligen (µg/dose)			600
Poly L-Arg (µg/dose)				1500
CVP addition		-	+	+	-
animal No.	1	5	5	5	5
	2	5	5	5
	3	5	5	5
	4	5	5	5
average antibody titer (GMT)		5.0	7.1	5.9	5.0
variance		0.0	2.9	2.5
seroconversion rate (antibody titer not less than 40, %)		0.0	0.0	0.0	0.0

[Table 26]

Administration of transnasal administration-type influenza vaccine (H5N1-type) and immune response evaluation test (NT) using Cynomolgus monkeys (Macaca fascicularis); before administration (blood samples were collected on 2010.1.28/measured on 2010.2.2)
group		1	2	3	4
vaccine HA antigen (µg/dose)		30	30	30	-
Ampligen (µg/dose)			600
Poly L-Arg (µg/dose)				1500
CVP addition		-	+	+	-
animal No.	1	5	10	5	5
	2	5	10	20
	3	5	5	10
	4	5	5	20
average antibody titer (GMT)		5.0	7.1	11.9	5.0
variance		0.0	2.9	7.5

[Table 27]

Administration of transnasal administration-type influenza vaccine (H5N1-type) and immune response evaluation test (NT) using Cynomolgus monkeys (Macaca fascicularis) after NT administration once (blood samples were collected 2010.2.18/measured on 2010.2.23)
group		1	2	3	4
vaccine HA antigen (µg/dose)		30	30	30	-
Ampligen (µg/dose)			600
Poly L-Arg (µg/dose)				1500
CVP addition		-	+	+	-
animal No.	1	5	10	20	5
	2	10	20	5
	3	20	20	10
	4	5	160	140
average antibody titer (GMT)		8.4	28.3	19.3	5.0
variance		7.1	71.8	64.5

[Table 28]

Administration of transnasal administration-type influenza vaccine (H5N1-type) and immune response evaluation test (NT) using Cynomolgus monkeys (Macaca fascicularis) after NT administration twice (blood samples were collected on 2010.3.4/measured on 2010.3.9)
group		1	2	3	4
vaccine HA antigen (µg/dose)		30	30	30	-
Ampligen (µg/dose)			600
Poly L-Arg (µg/dose)				1500
CVP addition		-	+	+	-
animal No.	1	20	20	80	5
	2	40	160	5
	3	40	160	80
	4	10	1280	40
average antibody titer (GMT)		23.8	160.0	33.6	5.0
variance		15.0	587.1	36.1

[Table 29]

Serum IgG ELISA titer after administration of transnasal administration-type influenza vaccine (H5N1-type) using Macaca fascicularis
group		1	2	3	4
antibody titer	Pre	141.4	168.2	200.0	100.0
	Post-3w	336.4	1131.4	237.8	50.0
	Post-5w	951.4	4525.5	1600.0	200.0
	Post-7w	400.0	5381.7	800.0	100.0

[Table 30]

Nasal swab IgA ELISA titer after administration of transnasal administration-type influenza vaccine (H5N1-type) using Cynomolgus monkeys (Macaca fascicularis)
group		1	2	3	4
antibody titer	Pre	0.7	1.5	1.4	1.1
	Post-3w	0.9	1.6	1.3	0.5
	Post-5w	0.7	4.4	2.9	0.6
	Post-7w	2.9	4.3	6.5	0.6

Claims (12)

1. A vaccine composition for nasal mucosal administration, comprising (i) an influenza virus antigen, (ii) polyriboinosinic polyribocytidylic acid (poly (I:C)), poly (I:CxU) or poly (IxU:C), and (iii) a carboxyvinyl polymer, wherein x is on average a number from 3 to 40.
2. The composition of claim 1, wherein the antigen is a subunit antigen or an inactivated antigen.
3. The composition of claim 2, wherein the subunit antigen comprises at least one subunit antigen selected from the group consisting of HA, NA, M1, M2, NP, PB1, PB2, PA and NS2 of influenza virus.
4. The composition of claim 2, wherein the subunit antigen comprises at least one subunit antigen selected from the group consisting of HA and NA.
5. The composition of claim 1, wherein the poly (I:CxU) is poly (I:C₁₂U).
6. A vaccine composition comprising an effective amount of (i) an influenza virus antigen, (ii) poly (I:C), poly (I:CxU) or poly (IxU:C), and (iii) a carboxyvinyl polymer, wherein x is on average a number from 3 to 40, said composition being for use in a method of preventing influenza, comprising a step of administering said composition at least once to the nasal mucosa of a subject in need thereof.
7. The composition for use according to claim 6, wherein the antigen is a subunit antigen or an inactivated antigen.
8. The composition for use according to claim 7, wherein the subunit antigen comprises at least one subunit antigen selected from the group consisting of HA, NA, M1, M2, NP, PB1, PB2, PA and NS2 of influenza virus.
9. The composition for use according to claim 7, wherein the subunit antigen comprises at least one subunit antigen selected from the group consisting of HA and NA.
10. The composition for use according to claim 6, wherein the poly (I:CxU) is poly (I:C₁₂U).
11. The composition for use according to claim 6, wherein the method comprises administering the composition at least twice.
12. The composition for use according to claim 11, wherein the method comprises administering the composition at an interval of at least 1 week.